Ycanth (Cantharidin) Patent Expiration, LOE Window & CMS Spending

Ycanth (Cantharidin) by Verrica: FDA Orange Book LOE 2041-02-19, 0 AB generics, $1.7M 2024 CMS Part D & Medicaid spend, and $8,220 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorVerrica
FDA Application & PathwayN212905 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2041-02-19
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$1.7M
2024 Medicare Part D Spend$15K
2024 Medicaid Spend$1.7M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($8,220 intro WAC)